SCHEMBL5769747

SCHEMBL5769747

O=C1c2c(c(O)c3ncccc3c2O)C(=O)N1C1CCCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
COMT P21964 7/20 0.42
KDM4E B2RXH2 6/20 0.40
OPRM1 P35372 2/20 0.39
FYN P06241 2/20 0.39
OPRD1 P41143 1/20 0.39
OPRL1 P41146 1/20 0.39
CHEK1 O14757 1/20 0.39
NTRK1 P04629 1/20 0.39
RET P07949 1/20 0.39
MET P08581 1/20 0.39
PDGFRB P09619 1/20 0.39
PIM1 P11309 1/20 0.39
FGFR1 P11362 1/20 0.39
PDGFRA P16234 1/20 0.39
LTK P29376 1/20 0.39
MAP2K2 P36507 1/20 0.39
FLT3 P36888 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK9 P45984 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6101777 0.83 ALDH1A1 (0.44) ALDH1A1KDM4ELMNASMN1; SMN2CYP2C19
SCHEMBL5768906 0.76 HTT (0.44) ALDH1A1COMTKDM4EOPRM1FYN
SCHEMBL5769757 0.72 MEN1 (0.45) ALDH1A1KDM4EOPRM1FYNL3MBTL1
SCHEMBL10832066 0.71 PADI4 (0.44) ALDH1A1KDM4EOPRM1OPRL1LMNA
SCHEMBL5766281 0.71 PARP1 (0.36) ALDH1A1ALOX15MEN1KMT2ATDP1
SCHEMBL5768327 0.70 KDM4E (0.48) ALDH1A1COMTKDM4EOPRM1FYN
SCHEMBL5766869 0.70 FEN1 (0.37) ALDH1A1KDM4ELMNATP53SMN1; SMN2
SCHEMBL1684227 0.69 CDK4 (0.48) ALDH1A1KDM4EOPRM1FYNL3MBTL1
SCHEMBL9212583 0.69 ALDH1A1 (1.00) ALDH1A1KDM4ELMNAHTTSMN1; SMN2
SCHEMBL5768949 0.68 L3MBTL3 (0.50) KDM4EL3MBTL1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211724-A1 Hiv integrase inhibitors VERSCHUEREN GASTON W 2006-09-21 US claimed
EP-1625130-A2 HIV INTEGRASE INHIBITORS Tibotec Pharmaceuticals Ltd. (IE) 2006-02-15 EP claimed
WO-2004096807-A2 HIV INTEGRASE INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2004-11-11 WO claimed
US-20060211724-A1 Hiv integrase inhibitors VERSCHUEREN GASTON W 2006-09-21 US disclosed
EP-1625130-A2 HIV INTEGRASE INHIBITORS Tibotec Pharmaceuticals Ltd. (IE) 2006-02-15 EP disclosed
WO-2004096807-A2 HIV INTEGRASE INHIBITORS TIBOTEC PHARMACEUTICALS LTD. (IE) 2004-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211724-A1 Hiv integrase inhibitors SULT1A1, SULT2A1, SULT1E1 ALDH1A1 1124/4885COMT 521/4885KDM4E 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.